Business
TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":" DENVER--(BUSINESS WIRE)--\nTriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that the Company will present data from recent research findings at the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, to be held March 23-28, 2024, in Salt Lake City, Utah.\n\n\nTriSalus will share data on the technical feasibility and safety of Pressure-Enabled Drug Delivery™ (PEDD) procedures in hypovascular tumors and initial data regarding our Pancreatic infusion technology, which is currently 510(k) cleared by the U.S. Food and Drug Administration (FDA) and in the Phase 1 clinical trial with nelitolimod in locally advanced pancreatic cancer.\n\n\nThe TriSalus approach seeks to address many of the key challenges associated with delivering therapeutics to pancreas tumors. In contrast to the liver, pancreas arteries feeding tumors are difficult to access and venous access affords anatomic advantages. Additionally, pancreatic tumors exhibit a dense, desmoplastic stroma that limits the delivery of therapeutics. The technology is designed to address these mechanical barriers and challenges by modulating pressure and flow, incorporating real-time pressure sensing capability to optimize safety and delivery.\n\n\n“The presentations featuring our PEDD approach illustrates that TriSalus is committed to and focused on transforming how therapeutics are delivered into biologically challenging liver and pancreas tumors. Mechanical barriers present in the tumor microenvironment, including high intra-tumoral pressure, may limit the performance of many therapeutic classes including embolics and immunotherapy. We look forward to our continued partnership with the interventional radiology community to improve outcomes in a variety of solid tumor indications,” noted Steven C. Katz, MD, FACS, Chief Medical Officer.\n\n\nPresentation details for SIR 2024 are as follows:\n\n\nPresentation: Clinical Efficacy of Pressure-Enabled Transarterial Embolization of Hypovascular, Treatment-Refractory Metastases.\nPresenting Author: Koustav Pal, MBBS, Postdoctoral Research Fellow at University of Texas MD Anderson Cancer Center\nDate: Sunday, March 24, 2024\nTime: 3:54 p.m. MT\nLocation: Salt La...